Biomatics Capital

Biomatics Capital is raising a second venture fund targeting $300 million, according to a regulatory filing https://www.sec.gov/Archives/edgar/data/1740118/000174011818000001/xslFormDX01/primary_doc.xml The Seattle-based firm is led by Julie Sunderland, who previously served as the director of program related investments for the Bill & Melinda Gates Foundation, and Boris Nikolic, previously the chief advisor for science and technology to Bill Gates, according to the firm’s website https://www.biomaticscapital.com/#team

Cambridge, Massachusetts-based eGenesis, a biotechnology company, has raised $38 million in Series A financing. Biomatics Capital and ARCH Venture Partners led the round with participation from Khosla Ventures, Alta Partners, Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings North America Ltd, Uprising, and Fan Ventures. In conjunction with the funding, Daniel S. Lynch was appointed executive chairman of eGenesis.

Bethesda, Maryland-based Aledade, which helps doctors form and operate accountable care organizations, has raised $20 million in funding. Biomatics Capital led the round with participation from other investors that included GV, Maryland Venture Fund, Venrock and ARCH Venture Partners.

Biomatics Capital Partners has closed its inaugural fund at $200 million, according to an SEC filing https://www.sec.gov/Archives/edgar/data/1672431/000167243116000003/xslFormDX01/primary_doc.xml Based in Seattle, the venture firm was established by Boris Nikolic, a former science adviser to Bill Gates.

Seattle-based Biomatics Capital Partners has filed to raise $150 million, according to a regulatory filing. The firm, which earlier this year invested in New York-based AiCure, was established by Boris Nikolic, who previously was a science adviser for Bill Gates, and Julie Sunderland, former director of program-related investments for the Bill & Melinda Gates Foundation.

Verve Therapeutics, a biotech company focused on treating cardiovascular disease, has raised $266.7 million for its IPO after pricing its over 14 million shares at $19 per share.

Cambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has raised $63 million in Series A2 funding.

Variant Bio, a biotech startup, has secured $16 million in Series A funding.

Cambridge, Massachusetts and Baltimore-based Thrive Earlier Detection Corp, a provider of earlier cancer detection solutions, has named Matt Franklin as chief commercial officer and Sarah Larson to its board of directors.

New York City-based AiCure, an artificial intelligence company, has secured $24.5 million in Series C funding. Palisades Growth Capital led the round with participation from Singtel Innov8, Asahi Kasei Corporation, Accelmed Growth Partners, SpringRock Ventures, Baird Capital, New Leaf Venture Partners, the Pritzker Group, Biomatics Capital, Tribeca Venture Partners and Silicon Valley Bank.

Cambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has named Dr. Andrew Bellinger as chief scientific officer. Dr. Bellinger is a general cardiologist at Brigham and Women’s Hospital. Verve’s backers include GV, ARCH Venture Partners, F-Prime Capital and Biomatics Capital.

Cambridge, Massachusetts and Baltimore-based Thrive Earlier Detection Corp, a healthcare company focused on incorporating earlier cancer detection into routine medical care, has named Seema Singh Bhan as senior vice president, public policy and external affairs. She is the former vice president, head of public policy for Foundation Medicine. Thrive Earlier Detection's backers include Third Rock Ventures, Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group and Exact Sciences.

Cambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has named Dr. Andrew Geall to its scientific advisory board. Geall is vice president of formulations, analytics and chemistry at Avidity Biosciences. Verve's backers include GV, ARCH Venture Partners, F-Prime Capital and Biomatics Capital.